FINWIRES · TerminalLIVE
FINWIRES

Transat A.T Says Increase in Aviation Fuel Prices Continues to Exert "Significant" Pressure on Global Energy Markets

By

Transat A.T (TRZ.TO) said the "significant" increase in aviation fuel prices, exacerbated by the prolonged closure of the Strait of Hormuz continues to exert "significant" pressure on global energy markets and is particularly affecting the entire airline industry, resulting in a substantial rise in its operating costs.

For the months of March and April, fuel surcharges had a limited impact on Transat's revenues and only marginally offset the negative impact of the increase in aviation fuel prices, it said. Taking into account the effect of existing hedging instruments, the increase in aviation fuel prices resulted, for these two months, in additional costs of about $70 million, or an increase of more than 75%, compared to March and April 2025.

The additional costs incurred by the company will be reflected in the results for the quarter ended April 30, 2026, which will be released mid-June 2026, it added.

"In addition to the cancellation of our flight program to Cuba until November 2026, the impact on our costs is material and could persist if the situation, which is beyond our control, were to continue," said Transat A.T Chief Executive Annick Guerard. "Despite the measures we are implementing, we are not able to fully eliminate its effects. In this context, we continue to closely monitor developments and adapt our actions accordingly."

Shares of the company closed down 1.5% to $2.66 on Thursday on the Toronto Stock Exchange.

Related Articles

Mining & Metals

BriaCell Therapeutics Developing Ovarian Cancer Immunotherapy Candidate

BriaCell Therapeutics (BCT.TO), up 1.6% in U.S. pre-market trading, is developing Bria-OVA+, its personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer, the company said on Friday.The company has licensed ovarian cancer cell-lines from American Type Culture Collection (ATCC) and has begun development activities to support production of Bria-OVA+ for potential clinical use."Following the encouraging efficacy and tolerability data from BriaCell's Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian," said Dr. William Williams, BriaCell chief executive officer."Bria-OVA+ reflects our broader strategy to build on the Bria-OTS+ platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women's health," he added.BriaCell shares are up US$0.065, to US$4.115 in New York trading.

$BCT.TO
Mining & Metals

Mako Mining's Q1 Net Income, Revenue Jump YoY on Higher Gold Prices

Mako Mining (MKO.V)'s net income and revenue increased in the first quarter amid higher gold prices, the company said Friday.Mako reported a net income of US$23.1 million, or $0.26 per share, for the three months ended March 31, climbing from $9.4 million, or $0.12 per share, booked in the year-ago period.Revenue jumped year over year to $68.6 million from $31.8 million, as gold sales rose to 13,721 ounces from 10,817 ounces. The average realized gold price surged to $4,902 per ounce from $2,915/oz.Mako will focus on lowering its cost of capital to accelerate accretive growth, the company said.

$MKO.V
Mining & Metals

Onex Q1 Net Earnings Fall, But Co Says Convex "Remains Well Positioned For Continued Growth In 2026"

Onex (ONEX.TO) reported lower net earnings for the first quarter, but singled out recent acquisition Convex as it "remains well positioned for continued growth in 2026".First quarter net earnings was US$129 million, compared to US$168 million in the corresponding year-ago quarter. Net earnings per diluted share in the quarter was US$1.76 per share, compared to US$2.36 per share in the year-ago quarter.Onex also released supplemental financial information for Convex Group Limited and reported that in Q1 2026, Convex generated adjusted net income of US$106 million, compared to adjusted net loss of $8 million in the year-ago quarter. Net income was negatively impacted by a US$50 million unrealized mark-to-market loss on its fixed income investment portfolio amid rising interest rates due to the broader macroeconomic volatility, it said. Excluding this non-operational accounting loss and one-time acquisition costs, Convex would have generated net income of US$156 million, the company added.The fair value of Onex' investment in Convex, a specialty property and casualty insurance and reinsurance company, was $4.0 billion as of March 31, 2026, an increase of $158 million, or 4%, since the acquisition closed in February 2026.The board of directors declared a dividend of C$0.10 per subordinate voting share payable on July 31, 2026, to shareholders of record on July 10, 2026, said the company. It is unchanged from the prior quarter."Onex carried significant momentum into 2026 and we continue to make good progress on our strategic objectives," said Bobby Le Blanc, Chief Executive Officer. "Convex delivered another strong quarter of underwriting profitability and net income and remains well positioned for continued growth in 2026."

$ONEX.TO